Cargando…

Risk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis Treatment

BACKGROUND: No study to date has focused on the changes in laboratory test results and related risk factors in patients with psoriasis treated with prolonged Cyclosporine A (CsA) therapy. OBJECTIVE: The objective of this study was to investigate the changes of laboratory values and related risk fact...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Bo Ri, Yang, Seungkeol, Doh, Eun Jin, Choi, Chong Won, Youn, Sang Woong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Dermatological Association; The Korean Society for Investigative Dermatology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839884/
https://www.ncbi.nlm.nih.gov/pubmed/29606810
http://dx.doi.org/10.5021/ad.2018.30.2.143
_version_ 1783304484271685632
author Kim, Bo Ri
Yang, Seungkeol
Doh, Eun Jin
Choi, Chong Won
Youn, Sang Woong
author_facet Kim, Bo Ri
Yang, Seungkeol
Doh, Eun Jin
Choi, Chong Won
Youn, Sang Woong
author_sort Kim, Bo Ri
collection PubMed
description BACKGROUND: No study to date has focused on the changes in laboratory test results and related risk factors in patients with psoriasis treated with prolonged Cyclosporine A (CsA) therapy. OBJECTIVE: The objective of this study was to investigate the changes of laboratory values and related risk factors in patients with psoriasis treated with CsA in a real-world setting. METHODS: Records of patients with psoriasis treated with CsA at an outpatient clinic were collected, and a Cox proportional hazards regression model was used. RESULTS: Of the 128 patients included in this study, 28 patients (21.9%) showed laboratory test abnormalities over a mean medication period of 11.6 months. Older age (hazard ratio [HR], 1.174; 95% confidence interval [CI], 1.068~1.370; p=0.007) and pre-existing kidney disease (HR, 0.008; 95% CI, 0~0.205; p=0.001) significantly increased the risk of renal dysfunction. Male sex was the only significant risk factor for liver enzyme elevation (HR, 0.284; 95% CI, 0.081~0.784; p=0.026) and uric acid abnormality (HR, 0.048; 95% CI, 0~0.372; p=0.046). CONCLUSION: This is an in-depth analysis of laboratory changes and related risk factors in patients with psoriasis treated with CsA. Liver is the most commonly affected organ of CsA toxicity. Older age, male sex, and presence of kidney disease were risk factors associated with laboratory abnormality during CsA treatment.
format Online
Article
Text
id pubmed-5839884
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The Korean Dermatological Association; The Korean Society for Investigative Dermatology
record_format MEDLINE/PubMed
spelling pubmed-58398842018-04-01 Risk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis Treatment Kim, Bo Ri Yang, Seungkeol Doh, Eun Jin Choi, Chong Won Youn, Sang Woong Ann Dermatol Original Article BACKGROUND: No study to date has focused on the changes in laboratory test results and related risk factors in patients with psoriasis treated with prolonged Cyclosporine A (CsA) therapy. OBJECTIVE: The objective of this study was to investigate the changes of laboratory values and related risk factors in patients with psoriasis treated with CsA in a real-world setting. METHODS: Records of patients with psoriasis treated with CsA at an outpatient clinic were collected, and a Cox proportional hazards regression model was used. RESULTS: Of the 128 patients included in this study, 28 patients (21.9%) showed laboratory test abnormalities over a mean medication period of 11.6 months. Older age (hazard ratio [HR], 1.174; 95% confidence interval [CI], 1.068~1.370; p=0.007) and pre-existing kidney disease (HR, 0.008; 95% CI, 0~0.205; p=0.001) significantly increased the risk of renal dysfunction. Male sex was the only significant risk factor for liver enzyme elevation (HR, 0.284; 95% CI, 0.081~0.784; p=0.026) and uric acid abnormality (HR, 0.048; 95% CI, 0~0.372; p=0.046). CONCLUSION: This is an in-depth analysis of laboratory changes and related risk factors in patients with psoriasis treated with CsA. Liver is the most commonly affected organ of CsA toxicity. Older age, male sex, and presence of kidney disease were risk factors associated with laboratory abnormality during CsA treatment. The Korean Dermatological Association; The Korean Society for Investigative Dermatology 2018-04 2018-02-21 /pmc/articles/PMC5839884/ /pubmed/29606810 http://dx.doi.org/10.5021/ad.2018.30.2.143 Text en Copyright © 2018 The Korean Dermatological Association and The Korean Society for Investigative Dermatology http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Bo Ri
Yang, Seungkeol
Doh, Eun Jin
Choi, Chong Won
Youn, Sang Woong
Risk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis Treatment
title Risk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis Treatment
title_full Risk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis Treatment
title_fullStr Risk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis Treatment
title_full_unstemmed Risk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis Treatment
title_short Risk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis Treatment
title_sort risk factors affecting adverse effects of cyclosporine a in a real-world psoriasis treatment
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839884/
https://www.ncbi.nlm.nih.gov/pubmed/29606810
http://dx.doi.org/10.5021/ad.2018.30.2.143
work_keys_str_mv AT kimbori riskfactorsaffectingadverseeffectsofcyclosporineainarealworldpsoriasistreatment
AT yangseungkeol riskfactorsaffectingadverseeffectsofcyclosporineainarealworldpsoriasistreatment
AT doheunjin riskfactorsaffectingadverseeffectsofcyclosporineainarealworldpsoriasistreatment
AT choichongwon riskfactorsaffectingadverseeffectsofcyclosporineainarealworldpsoriasistreatment
AT younsangwoong riskfactorsaffectingadverseeffectsofcyclosporineainarealworldpsoriasistreatment